155452-87-2

Basic information

• Product Name: (R,S)-Z-3-AMINO-7-CHLORO-2-OXO-5-PHENYL-1,4-BENZODIAZEPINE
• Synonyms: RARECHEM EM WB 0239;(R,S)-Z-3-AMINO-7-CHLORO-2-OXO-5-PHENYL-1,4-BENZODIAZEPINE;Z-(R,S)-3-AMINO-7-CHLORO-2-OXO-5-PHENYL-1,4-BENZODIAZEPINE;Z-(R,S)-3-amino-7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine≥ 98% (HPLC)
• CAS NO: 155452-87-2
• Molecular Formula: C₂₃H₁₈ClN₃O₃
• Molecular Weight: 419.86
• Mol File: 155452-87-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Store at 0-5°C
• CAS DataBase Reference: (R,S)-Z-3-AMINO-7-CHLORO-2-OXO-5-PHENYL-1,4-BENZODIAZEPINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R,S)-Z-3-AMINO-7-CHLORO-2-OXO-5-PHENYL-1,4-BENZODIAZEPINE(155452-87-2)
• EPA Substance Registry System: (R,S)-Z-3-AMINO-7-CHLORO-2-OXO-5-PHENYL-1,4-BENZODIAZEPINE(155452-87-2)

Safety Data

• Hazardous Substances Data: 155452-87-2(Hazardous Substances Data)

Usage

Chemical Properties

White amorphous powder

Upstream product

• 719-59-5 5-chloro-2-aminobenzophenone 
• 517874-18-9 (Benzotriazol-1-yl-chlorocarbonyl-methyl)-carbamic acid benzyl ester 
• 621-84-1 O-benzyl carbamate 

Downstream Products

• 1300087-15-3 benzyl (8-chloro-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)carbamate 
• 1300089-51-3 benzyl (7-chloro-5-phenyl-2-thioxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
• 209985-17-1 3-(benzyloxycarbonyl)-amino-7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one 
• 676127-92-7 3-amino-7-chloro-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one hydrobromide 

Relevant articles and documents

Discovery of epigenetic regulator i-bet762: Lead optimization to afford a clinical candidate inhibitor of the bet bromodomains

The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation in a phase I/II clinical trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.